Literature DB >> 7159207

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man.

A E Balant-Gorgia, P Schulz, P Dayer, L Balant, A Kubli, C Gertsch, G Garrone.   

Abstract

We have measured the metabolites (demethylated and hydroxylated) of amitriptyline in a group of seven normal volunteers. They were phenotyped as extensive or poor metabolizers using debrisoquine and bufuralol. The results demonstrate that the oxidative metabolism (aliphatic hydroxylation) of amitriptyline is under the same genetic control as that of debrisoquine and bufuralol. However, phenotypic polymorphism cannot be used to predict amitriptyline blood concentration after a single oral dose, since the principal metabolic pathway of amitriptyline is demethylation and not aliphatic hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159207     DOI: 10.1007/bf02141782

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  14 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

3.  Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolism.

Authors:  D W Nebert
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-22

4.  Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites.

Authors:  B Vandel; M Sandoz; S Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

6.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

7.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

8.  Active metabolites of imipramine and desipramine in man.

Authors:  W Z Potter; H M Calil; T A Sutfin; A P Zavadil; W J Jusko; J Rapoport; F K Goodwin
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

9.  Interindividual differences in amitriptyline demethylation.

Authors:  D E Rollins; G Alván; L Bertilsson; J R Gillette; B Mellström; F Sjöqvist; L Träskman
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  18 in total

Review 1.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

2.  Metabolism of amineptine in rat, dog and man.

Authors:  L Grislain; P Gelé; N Bromet; W Luijten; J P Volland; E Mocaer; A Kamoun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 3.  Discrepancies between pharmacokinetic studies of amitriptyline.

Authors:  P Schulz; P Dick; T F Blaschke; L Hollister
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

4.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

5.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

Review 6.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.

Authors:  Jónrit Halling; Pál Weihe; Kim Brosen
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

8.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

Authors:  C Nordin; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

10.  Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; P Dayer; J M Aeschlimann; G Garrone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.